Regarding "Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs"

Oncologist. 2023 Jul 5;28(7):e588-e589. doi: 10.1093/oncolo/oyad130.

I-Hsuan Su¹, Jennifer L Lund^{1

2}, Charles E Gaber³, Hanna K Sanoff^{2

4}, Paula D Strassle⁵, Emilie D Duchesneau^{1

2}

¹ Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
³ Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois-Chicago, Chicago, IL, USA.
⁴ Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
⁵ Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD, USA.

Abstract

This letter to the editor expresses concerns related to immortal time bias that may partially account for recently published study results.